# OnCo record nct06827236 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06827236/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06827236", "NCT06827236" ;
  schema:name "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer"@en ;
  schema:description "A phase 1/2 trial of Trastuzumab pamirtecan and PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06827236/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06827236> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-04-23" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-pamirtecan/>, <https://onco.cc/drugs/pm8002/> ;
  onco:companies <https://onco.cc/companies/biontech/>, <https://onco.cc/companies/dualitybio/> .